A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Trial Profile

A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy-BioTech Tools (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors ASIT biotech; BioTech Tools
  • Most Recent Events

    • 03 Jul 2017 Results published in an ASIT biotech Media Release.
    • 03 Jul 2017 According to an ASIT biotech media release, data from this study wiere presented at at the European Academy of Allergy and Clinical Immunology (EAACI) 2017.
    • 30 May 2017 According to an ASIT biotech media release, data from this study will be presented at at the European Academy of Allergy and Clinical Immunology (EAACI) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top